波士顿科学Boston Scientific Corporation (BSX) 2005年年度报告「NYSE」.pdf

1、There are millions of reasons we set such high standards for everything we do.A N N U A L R E P O R T 2 0 0 5PHASE I Less-Invasive MedicinePioneer/LeaderPHASE III Stent Integration&Drug-Eluting Stent LeadershipPHASE II Strategic Mass(Via Acquisitions)Revenue in MillionsPHASE IVNext Chapter$0$1,000$2

2、,000$3,000$4,000$5,000$6,000$7,000050403020100999897969594939291908988878685848382818079FROM PIONEER TO LEADERBoston Scientific has achieved an impressive compound annual growth rate of more than 35 percentover the past 26 years.Our rapid rise as an innovator and acquirer has brought us to a powerfu

3、lleadership position,with more than 80 percent of our sales from market-leading products sold inthe markets we serve.The high standards that have enabled us to achieve this success are the keyto our future.1Annual Report 2005Letter to Shareholders&Employees2The Higher Standard Imperative10Higher Sta

4、ndards for Clinical Trials14Higher Standards for Medical Information18Higher Standards for Our Entire Company22Higher Standards for Improving Lives30Consolidated Financial Statements37To Our Shareholders and EmployeesThe year 2005 was a time of great change in the medical device industry.Mergers and

5、 acquisitionscontinued at a quickening pace,and new innovations reshaped the medical landscape.But perhapsthe years most noteworthy theme was the publics growing concern with the way our industrygenerates and shares information about drugs and devices.This concern,which has beenheightened by high-pr

6、ofile lawsuits and revelations about editorial practices in reporting clinicaltrial findings,means that the standards a company uses to run its business take on greaterimportance than ever.At Boston Scientific,we see the question of standards as a scientificrequirement and an ethical imperative.As t